NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Rhea-AI Summary

NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial Phase 1 dose‑escalation results from the NEO212-01 trial.

The presentation will cover safety and toxicity data, dose‑escalation observations, pharmacokinetics, and planned regulatory next steps for the oral bioconjugated temozolomide program, with participation from company management and independent Scientific Advisory Board members.

News Market Reaction – NTHI

+1.29%

+1.29% Session close to close

In the Feb 27 session, NTHI gained 1.29%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules an investor call to present the full Phase 1 dose-escalation readout fro...

Analysis

This announcement schedules an investor call to present the full Phase 1 dose-escalation readout from the NEO212-01 Phase 1/2 trial, including safety, toxicity, dose-escalation findings, pharmacokinetics, and regulatory next steps. Historically, a similar conferences/clinical trial call produced a modest 2.74% gain. Investors may focus on how NEO212 data complements prior NEO100 results, the clarity of the development path, and how emerging clinical evidence fits alongside recent financing and registration activity.

Key Figures

Conference date: March 4, 2026 Call time PT: 6:00 a.m. PT Call time ET: 9:00 a.m. ET +2 more

5 metrics

Conference date March 4, 2026 Investor conference call and webcast

Call time PT 6:00 a.m. PT Scheduled start of investor call

Call time ET 9:00 a.m. ET Scheduled start of investor call

Trial phase Phase 1/2 NEO212-01 clinical trial design

Dose-escalation phase Phase 1 Dose-escalation portion to be presented

Previous Conferences,clinical trial Reports

1 past event · Latest: Nov 07 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 07	Conference data update	Positive	+2.7%	Investor call highlighting NEO100-1 Phase 1/2a and compassionate use data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior conference/clinical update call with similar tagging saw a modest positive price reaction.

Recent Company History

Over the past few months, NeOnc has combined clinical and capital markets activity. A November 2025 conference call on NEO100 clinical data produced a 2.74% gain. Subsequent news included a Q3 2025 update with a $50.0 million strategic partnership and advancing NEO212, updated NEO100 clinical results with favorable efficacy and tolerability, AI-driven preclinical findings enhancing NEO100’s potency, and a January 2026 PIPE expected to raise up to $16 million. Today’s planned NEO212-01 Phase 1 dose-escalation readout fits this pattern of data-centric catalysts.

Key Terms

dose-escalation, phase 1/2, toxicity, central nervous system (cns), +4 more

8 terms

dose-escalation medical

"present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2"

Dose-escalation is the part of an early-stage clinical trial where researchers gradually increase a drug’s dose in small groups of participants to find the safest and most effective amount. Think of it like turning up the volume slowly to find the sweet spot: investors watch these results closely because they reveal safety risks, potential effectiveness, and how quickly a drug can move to later trials or approval, all of which affect the development timeline and commercial prospects.

phase 1/2 medical

"NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc’s proprietary bioconjugated"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

toxicity medical

"full Phase 1 NEO212-01 Readout for Dosing and Toxicity"

Toxicity is the degree to which a drug, chemical, or product causes harmful effects in people or the environment; think of it as how poisonous or damaging something is at a given dose. For investors, toxicity matters because high or uncertain toxicity can block regulatory approval, trigger costly additional testing, recalls, legal liabilities, or limit market use—effects that can reduce revenue, raise costs, and increase investment risk.

central nervous system (cns) medical

"therapies for central nervous system (CNS) cancers, today announced today"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

bioconjugated temozolomide (tmz) medical

"evaluating NeOnc’s proprietary bioconjugated temozolomide (TMZ) platform in an oral"

Bioconjugated temozolomide (TMZ) is the chemotherapy drug temozolomide chemically linked to a targeting molecule or carrier so the drug can be delivered more precisely to tumor cells. For investors, this matters because targeted delivery can change a drug’s effectiveness, side-effect profile, development cost, patent protection and market potential—think of it like attaching a guided missile to a standard bomb to hit the target more reliably and reduce collateral damage.

pharmacokinetic medical

"including safety and toxicity data, dose-escalation observations, pharmacokinetic findings,"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

scientific advisory board (sab) technical

"management team and independent members of the Company’s Scientific Advisory Board (SAB)"

A scientific advisory board (SAB) is a group of external experts—scientists, clinicians or technical specialists—who advise a company on research, product development and regulatory strategy. For investors, an SAB matters because respected, independent experts can validate the science, flag technical or regulatory risks, and increase credibility with partners and regulators, much like a trusted consultant improving a project's chances of success.

webcast technical

"will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time.

During the call, members of the NeOnc management team and independent members of the Company’s Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc’s proprietary bioconjugated temozolomide (TMZ) platform in an oral formulation for patients with CNS malignancies.

The discussion will include an update on the Phase 1 dose-escalation portion of the NEO212-01 clinical trial, including safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps.

Featured Participants:

• Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board
• Dr. Alexandra Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board
• NTHI Management Team:
  • Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President
  • Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer
  • Dr. Josh Neman, PhD – Chief Clinical Officer
  • Keithly Garnett – Chief Financial Officer
    

Conference Call Details:

• Date: March 4, 2026
• Time: 6:00 a.m. PT / 9:00 a.m. ET
• Webcast: A live webcast can be accessed at: https://www.webcaster5.com/Webcast/Page/3151/53708 or by visiting https://investors.neonc.com
  

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.


NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit https://neonc.com

Important Cautions Regarding Forward Looking Statements


This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:

info@neonc.com 


Investor Contact:


James Carbonara


Hayden IR


(646)-755-7412

james@haydenir.com

FAQ

When is NeOnc Technologies (NTHI) presenting NEO212-01 Phase 1 dose‑escalation results?

NeOnc will present on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET. According to the company, management and independent SAB members will discuss initial dose‑escalation safety, toxicity, pharmacokinetics, and regulatory next steps during a live webcast.

What data will NeOnc (NTHI) share for the NEO212-01 Phase 1 trial on March 4, 2026?

The company will present safety, toxicity, dose‑escalation observations, and pharmacokinetic findings. According to the company, the update focuses on the Phase 1 dose‑escalation portion of NEO212-01 and planned regulatory next steps for the oral TMZ bioconjugate.

How can investors access the NeOnc (NTHI) March 4, 2026 investor webcast for NEO212-01 results?

Investors can access a live webcast at https://www.webcaster5.com/Webcast/Page/3151/53708 or via the company's investor site. According to the company, the webcast will stream the March 4, 2026 presentation by management and SAB members covering the Phase 1 data.

Who will present NeOnc's NEO212-01 Phase 1 dose‑escalation readout on March 4, 2026?

Presenters include NeOnc management and independent SAB members such as Dr. Henry S. Friedman and Dr. Alexandra Miller. According to the company, the roster also features the CEO, CMO, CCO, and CFO during the March 4, 2026 call and webcast.

Will NeOnc (NTHI) discuss regulatory next steps for NEO212-01 during the March 4, 2026 call?

Yes, the presentation will include planned regulatory next steps for the NEO212-01 program. According to the company, management will review regulatory considerations alongside safety, toxicity, dose‑escalation observations, and pharmacokinetic findings during the March 4 webcast.